Study type: Human research · Status: Verified against declared source
Randomized, placebo-controlled, double-blind, pilot trial to investigate safety and efficacy of Cerebrolysin in patients with aneurysmal subarachnoid hemorrhage.
BMC neurology · 2020
Study scale: Trial Registration Number: NCT01787123.
Abstract only: Open source record
Product or molecular entity relationships
- Cerebrolysin: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.
Plain-language verified summary
Question
Global functional outcome was evaluated by an independent assessor, a registered nurse, at 30 days, 3 months and 6 months after ictus using the following instruments: the Extended Glasgow Outcome Scale (GOSE), mRS and BI.
Methods
The optimum dose for Cerebrolysin in the setting of aneurysmal SAH requires further investigation.
Scale or participants
Trial Registration Number: NCT01787123.
Key findings
This was a prospective, randomized, double-blind, placebo-controlled, single-center, parallel-group pilot study.
Limitations and uncertainty
Use of Cerebrolysin in addition to standard-of-care management of aneurysmal SAH is safe, well tolerated and feasible.
Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.